Kamada Plans Three More Biosimilar Launches In Israel

Post Approval, Company Expects Sales Of $5m-$7m From The Candidates

 
• By Akriti Seth
  
Israel flag
Kamada enters into two new agreements to launch three biosimilars in Israel • Source: Shutterstock

More from Biosimilars

More from Products